Literature DB >> 26796509

Osteogenic markers are reduced in bone-marrow mesenchymal cells and femoral bone of young spontaneously hypertensive rats.

Thamine Landim de Barros1, Victor Gustavo Balera Brito2, Caril Constante Ferreira do Amaral1, Antonio Hernandes Chaves-Neto2, Ana Paula Campanelli3, Sandra Helena Penha Oliveira4.   

Abstract

AIMS: Spontaneously hypertensive rats (SHR) and normotensive rats (W) has significant changes in bone metabolism. The purpose of this study was to investigate whether, the genetic predisposition, is sufficient to induce changes in the osteoblast differentiation and osteogenic markers in the BMSCs or in the femoral bone. For this we use young SHR rats without hypertension, but, with genetic predisposition in compared with young W. MAIN
METHODS: BMSCs were cultured in a proliferation medium (MEM) or osteogenic medium. Osteogenic differentiation was analyzed by proliferation, total protein, alkaline phosphatase, mineralization, and the mRNA expression of RUNX-2, β-cathenin, osterix, bone morphogenetic protein-2(BMP-2), osteocalcin (OCN), bone sialoprotein (BSP), collagen type I (Col I), and osteopontin (OPN). KEY
FINDINGS: Osteoblast differentiation in SHR BMSCs (SHRC) had an increased proliferation compared with W BMSCs (WC). After osteogenic induction, there was greater reduction in proliferation in SHR (SHROM) than in W, in the same condition (WOM). On day 7, although no significant difference in the ALP activity was observed between SHROM and WOM, poor mineralization and osteoblast differentiation was noted in SHROM. The Osterix and β-catenin are involved in the reduced osteoblast differentiation in SHROM. The decreased expression of osteoblast-associated proteins such as OCN, BSP, COL I and OPN revealed poor quality of extracellular matrix (ECM) in SHROM. In the femoral bone, the immunostaining of COL1, BALP, OPN and OCN in SHR was decreased compared with the W. TRAP-positive immunoreactions were observed in major extension in the SHR femur. SIGNIFICANCE: This study is the first to compare osteoblast differentiation in vitro and femoral bone from SHR and W rats. Our results demonstrated that young SHR (4weeks old), without hypertension, but with genetic predisposition, had alterations in osteoblast differentiation of BMSCs and in the femoral bone when compared with their progenitor strain, W.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone markers expression; Femur; Mesenchymal stem cells; Osteogenic differentiation; Spontaneously hypertensive rats (SHR)

Mesh:

Year:  2016        PMID: 26796509     DOI: 10.1016/j.lfs.2016.01.015

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

1.  Systemic Dietary Hesperidin Modulation of Osteoclastogenesis, Bone Homeostasis and Periodontal Disease in Mice.

Authors:  Vinícius de Paiva Gonçalves; Marta Liliana Musskopf; Angeliz Rivera-Concepcion; Christina Yu; Sing Wai Wong; Stephen A Tuin; Yizu Jiao; Cristiano Susin; Luís Carlos Spolidorio; Patricia Almeida Miguez
Journal:  Int J Mol Sci       Date:  2022-06-26       Impact factor: 6.208

2.  High-resolution mapping of a novel rat blood pressure locus on chromosome 9 to a region containing the Spp2 gene and colocalization of a QTL for bone mass.

Authors:  Ying Nie; Sivarajan Kumarasamy; Harshal Waghulde; Xi Cheng; Blair Mell; Piotr J Czernik; Beata Lecka-Czernik; Bina Joe
Journal:  Physiol Genomics       Date:  2016-04-25       Impact factor: 3.107

3.  Dose-dependence of PTH-related peptide-1 on the osteogenic induction of MC3T3-E1 cells in vitro.

Authors:  Jianping Wang; Jingfeng Li; Liang Yang; Yichi Zhou; Yi Wang
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

4.  Effects of strength training on osteogenic differentiation and bone strength in aging female Wistar rats.

Authors:  Monique Patricio Singulani; Camila Tami Stringhetta-Garcia; Leandro Figueiredo Santos; Samuel Rodrigues Lourenço Morais; Mário Jefferson Quirino Louzada; Sandra Helena Penha Oliveira; Antonio Hernandes Chaves Neto; Rita Cássia Menegati Dornelles
Journal:  Sci Rep       Date:  2017-02-17       Impact factor: 4.379

5.  Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease.

Authors:  Victor Gustavo Balera Brito; Mariana Sousa Patrocinio; Maria Carolina Linjardi de Sousa; Ayná Emanuelli Alves Barreto; Sabrina Cruz Tfaile Frasnelli; Vanessa Soares Lara; Carlos Ferreira Santos; Sandra Helena Penha Oliveira
Journal:  Front Pharmacol       Date:  2020-11-11       Impact factor: 5.810

6.  Mast cells contribute to alveolar bone loss in Spontaneously Hypertensive Rats with periodontal disease regulating cytokines production.

Authors:  Victor Gustavo Balera Brito; Mariana Sousa Patrocinio; Maria Carolina Linjardi Sousa; Ayná Emanuelli Alves Barreto; Sabrina Cruz Tfaile Frasnelli; Vanessa Soares Lara; Carlos Ferreira Santos; Sandra Helena Penha Oliveira
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

7.  BMP-2 Enhances Osteogenic Differentiation of Human Adipose-Derived and Dental Pulp Stem Cells in 2D and 3D In Vitro Models.

Authors:  Sara Martin-Iglesias; Lara Milian; María Sancho-Tello; Rubén Salvador-Clavell; José Javier Martín de Llano; Carmen Carda; Manuel Mata
Journal:  Stem Cells Int       Date:  2022-03-04       Impact factor: 5.443

Review 8.  Factors affecting the periapical healing process of endodontically treated teeth.

Authors:  Roberto Holland; João Eduardo Gomes; Luciano Tavares Angelo Cintra; Índia Olinta de Azevedo Queiroz; Carlos Estrela
Journal:  J Appl Oral Sci       Date:  2017 Sep-Oct       Impact factor: 2.698

9.  Expression profiles of the Wnt/β-catenin signaling-related extracellular antagonists during proliferation and differentiation in human osteoblast-like cells.

Authors:  Alma Y Parra-Torres; Juana Enríquez; Rogelio F Jiménez-Ortega; Nelly Patiño; Manuel De Jesús Castillejos-López; Luz M Torres-Espíndola; Eric G Ramírez-Salazar; Rafael Velázquez-Cruz
Journal:  Exp Ther Med       Date:  2020-10-23       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.